Buy NORDITROPIN NORDILET 10MG/1.5ML
NORDITROPIN NORDILET 10MG is used to treat growth hormone deficiency in children (to replace growth hormone that they are unable to produce enough of naturally) and to correct growth failure in children born small for gestational age (SGA) who do not catch up in growth by 2 years or later.
NORDITROPIN NORDILET 10MG is prefilled and premixed. This means you don’t have to load the growth hormone with cartridges Users of Norditropin Nordilet Pen have access to NordiCare patient support, which can help you with Norditropin Nordilet Pen 30IU insurance issues you may have Norditropin Nordilet Pen offers multiple doses which means most patients can use the pen several times before the medicine runs out.
Buy NORDITROPIN NORDILET 10MG is indicated for the treatment of pediatric patients with:
- growth failure due to inadequate secretion of endogenous growth hormone (GH),
- short stature associated with Noonan syndrome,
- short stature associated with Turner syndrome,
- short stature born small for gestational age (SGA) with no catch-up growth by age 2 years to 4 years of age,
- Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range,
- growth failure due to Prader-Willi syndrome (PWS).
Dosage NORDITROPIN NORDILET
Norditropin NordiLet is a pre-filled pen designed to be used with NovoFine disposable needles. The dose is delivered in clicks. Norditropin NordiLet delivers 1–29 clicks in increments of 1 click for each injection.
5 mg/1.5 ml: The dose per click is 0.0667 mg (5 mg/1.5 ml). In the package leaflet for each strength a range of doses in mg per number of clicks is given in a conversion table.
10 mg/1.5 ml: The dose per click is 0.1333 mg (10 mg/1.5 ml). In the package leaflet for each strength a range of doses in mg per number of clicks is given in a conversion table.
The dosage is individual and must always be adjusted in accordance with individual’s clinical and biochemical response to therapy. Generally, daily subcutaneous injection in the evening is recommended. The injection site should be varied to prevent lipoatrophy.
For the injection procedure, please see the instruction manual for Norditropin NordiLet 5 mg/1.5 ml and Norditropin NordiLet 10 mg/1.5 mL.
Patients should be reminded to wash their hands thoroughly with soap and water and/or disinfectant prior to any contact with Norditropin NordiLet.
Norditropin NordiLet should not be shaken vigorously at any time.
General recommendations for dosages are shown as follows.
Children: Growth hormone deficiency: 0.025 to 0.035 mg/kg/day or 0.7 to 1.0 mg/m2/day.
When GHD persists after growth completion, growth hormone treatment should be continued to achieve full somatic adult development including lean body mass and bone mineral accrual.
In children with Turner syndrome: 0.045 to 0.067 mg/kg/day or 1.3 to 2.0 mg/m2/day.
In children with Chronic renal disease: 0.050 mg/kg/day or 1.4 mg/m2/day.
In children born small for gestational age (SGA): 0.033 to 0.067 mg/kg/day or 1.0 to 2.0 mg/m2/day.
Adults: Replacement therapy: The dosage must be adjusted to the need of the individual patient.
In patients with childhood onset GHD, the recommended dose to restart is 0.2-0.5 mg/day with subsequent dose adjustment on the basis of IGF-I concentration determination.
In patients with adult onset GHD, it is recommended to start treatment with a low dose 0.1-0.3 mg/day and to increase the dosage gradually at monthly intervals in order to meet the need of the individual patient. Serum IGF-I can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement, are under-treated while men are over-treated.
Dose requirements decline with age. Maintenance dosages vary from person to person, but seldom exceed 1.0 mg/day (equal to 3 IU/day).
Side effects NORDITROPIN NORDILET 10MG
Like all medicines, NORDITROPIN NORDILET 10MG can cause side effects, although not everybody gets them.
Effects seen in children and adults (unknown frequency):
- Rash; wheezing; swollen eyelids, face or lips; complete collapse. Any of these may be signs of allergic reactions
- Headache, eyesight problems, feeling sick (nausea) and being sick (vomiting). These may be signs of raised pressure in the brain
- Serum thyroxin levels may decrease
- Hyperglycaemia (elevated levels of blood glucose).
If you get any of these effects, see a doctor as soon as possible. Stop using Norditropin NordiFlex until your doctor says you can continue treatment.
Formation of antibodies directed against somatropin has been rarely observed during Norditropin therapy.
Increased levels of liver enzymes have been reported.
Cases of leukaemia and relapse of brain tumours have also been reported in patients treated with somatropin (the active ingredient in Norditropin NordiFlex), although there is no evidence that somatropin was responsible.
If you think you are suffering from any of these diseases, speak to your doctor.
Additional side effects in children:
Uncommon (may affect up to 1 in 100 children):
- Redness, itching and pain in the area of injection.
Rare (may affect up to one in 1,000 children):
- Muscle and joint pain
- Swollen hands and feet due to fluid retention.
In rare cases, children using NORDITROPIN NORDILET 10MG have experienced hip and knee pain or have started limping. These symptoms may be caused by a disease affecting the top of the thigh bone (Legg-Calvé disease) or because the end of the bone has slipped from the cartilage (slipped capital femoral epiphysis) and may not be due to Norditropin NordiFlex.
In children with Turner syndrome, a few cases of increased growth of hands and feet compared to height have been observed in clinical trials.
A clinical trial in children with Turner syndrome has shown that high doses of Norditropin can possibly increase the risk of getting ear infections.